Etrolizumab Recruiting Phase 3 Trials for Crohn's Disease (CD) Treatment

RecruitingTreatment3 IdentifierTitleDrugs
NCT02394028A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants With Moderately to Severely Active Crohn's Disease (CD)
NCT02403323Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144